Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese Patients With Acute Coronary Syndrome　– Randomized, Double-Blind, Phase III PHILO Study

Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese Patients With Acute Coronary Syndrome　– Randomized, Double-Blind, Phase III PHILO Study –

Published:2015 Issue:11 Volume:79 Page:2452-2460
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Goto Shinya¹,Huang Chien-Hua²,Park Seung-Jung³,Emanuelsson Håkan⁴,Kimura Takeshi⁵

Affiliation:

1. Department of Medicine (Cardiology), Tokai University School of Medicine

2. Department of Emergency Medicine and Internal Medicine, National Taiwan University

3. Division of Cardiology, Ulsan School of Medicine

4. AstraZeneca

5. Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/79/11/79_CJ-15-0112/_pdf

Reference37 articles.

1. 1. Takii T, Yasuda S, Takahashi J, Ito K, Shiba N, Shirato K, et al. Trends in acute myocardial infarction incidence and mortality over 30 years in Japan: Report from the MIYAGI-AMI Registry Study. Circ J 2010; 74: 93–100.

2. 2. Daida H, Miyauchi K, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, et al. Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: Prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry. Circ J 2013; 77: 934–943.

3. 3. Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, et al. Management of acute coronary syndromes. Variations in practice and outcome; Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177–1189.

4. 4. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative. JAMA 2004; 292: 2096–2104.

5. 5. Nakatani D, Sakata Y, Suna S, Usami M, Matsumoto S, Shimizu M, et al. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J 2013; 77: 439–446.

Cited by 225 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes of adjusted-dose versus standard-dose prasugrel in East Asian patients with acute myocardial infarction;International Journal of Cardiology;2024-09

2. Comparative Effectiveness and Safety of Ticagrelor and Clopidogrel in Patients With or Without Chronic Liver Disease: A Nationwide Cohort Study;The American Journal of Medicine;2024-08

3. Low-Dose Prasugrel vs. Standard-Dose Clopidogrel for Patients Undergoing Percutaneous Coronary Intervention;Circulation Journal;2024-07-09

4. Review of the Ticagrelor Trials Evidence Base;Journal of the American Heart Association;2024-06-04

5. Ticagrelor potentiates cardioprotection by remote ischemic preconditioning: the ticagrelor in remote ischemic preconditioning (TRIP) randomized clinical trial;Hellenic Journal of Cardiology;2024-06